Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years’ Therapy-Reference-Cited by-同舟云学术

Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years’ Therapy

Published:2023-09 Issue:9 Volume:11 Page:2715-2723
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Fyles Fred^ORCID,Nuttall Amy,Joplin Hannah,Burhan Hassan

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference56 articles.

1. Diagnosis and management of severe asthma;Chung;Semin Respir Crit Care Med,2018

2. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur Respir J,2014

3. Severe asthma in a general population study: prevalence and clinical characteristics;Rönnebjerg;J Asthma Allergy,2021

4. Clinical and economic burden of severe asthma: a French cohort study;Nordon;Respir Med,2018

5. The global burden of asthma;Braman;Chest,2006

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologics in T2 Severe Asthma: Unveiling Different Effectiveness by Real-World Indirect Comparison;Journal of Clinical Medicine;2024-08-13

2. Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience;Frontiers in Pharmacology;2024-08-08

3. Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study);European Respiratory Journal;2024-06-06

4. Anti–IL-4R versus anti–IL-5/5R after anti–IL-5/5R failure in asthma: An emulated target trial;Journal of Allergy and Clinical Immunology;2024-06

5. Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study;Journal of Clinical Medicine;2024-05-20